AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10764848 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopia assessment
Number of subjects: 0
Study 8831648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 36
Study 8831648 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 36
Study 1331618 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interview regarding risk behavior
Number of subjects: 313
Study 1331618 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview plus one group AIDS education session
Number of subjects: 313
Study 1331618 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview, AIDS education plus optional HIV testing
Number of subjects: 313
Study 1331618 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol users
Number of subjects: 313
Study 1331618 — intervention group
Group type: COMPARATOR
Intervention: Nondrinkers
Number of subjects: 313
Study 6382224 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg twice a day
Number of subjects: 20
Study 6382224 — intervention group
Group type: EXPERIMENTAL
Intervention: mefruside 25 mg once a day
Number of subjects: 20
Study 31829187 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic rumen‐protected fat (RPF) supplement (0.45 kg/d)
Number of subjects: 202
Study 31829187 — intervention group
Group type: COMPARATOR
Intervention: Control pellets (CON)
Number of subjects: 202
Study 29342058 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular repair
Number of subjects: 15
Study 29342058 — intervention group
Group type: COMPARATOR
Intervention: No capsular repair
Number of subjects: 15
Study 29342058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Repaired and Unrepaired)
Number of subjects: 15
Study 27208823 — intervention group
Group type: EXPERIMENTAL
Intervention: TRL from MetS patients with endothelial dysfunction (n=6)
Number of subjects: 40
Study 27208823 — intervention group
Group type: EXPERIMENTAL
Intervention: TRL from both MetS groups
Number of subjects: 40
Study 27208823 — intervention group
Group type: EXPERIMENTAL
Intervention: TRL from MetS patients with endothelial dysfunction
Number of subjects: 40
Study 27208823 — intervention group
Group type: EXPERIMENTAL
Intervention: TRL-triglyceride (%)
Number of subjects: 40
Study 25556460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with DCF chemotherapy
Number of subjects: 34
Study 25556460 — intervention group
Group type: COMPARATOR
Intervention: Standard DCF chemotherapy
Number of subjects: 34
Study 22483480 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ureteric stent removal at 8 days
Number of subjects: 90
Study 22483480 — intervention group
Group type: COMPARATOR
Intervention: Routine ureteric stent removal at 15 days
Number of subjects: 90
Study 22483480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bacteriuria
Number of subjects: 90
Study 22483480 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriuria causative organisms
Number of subjects: 90
Study 22483480 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL producing organisms
Number of subjects: 90
Study 17393217 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-functional food (n = 16)
Number of subjects: 30
Study 17393217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study 15951292 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sequential (HDS) chemotherapy plus high-dose mitoxantrone and melphalan with autologous stem-cell transplantation (ASCT)
Number of subjects: 130
Study 15951292 — intervention group
Group type: COMPARATOR
Intervention: Outpatient dose-dense chemotherapy regimen (MegaCEOP)
Number of subjects: 130
Study 15951292 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sequential (HDS) chemotherapy plus ASCT
Number of subjects: 130
Study 12492248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 944
Study 12492248 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 944
Study 9579297 — intervention group
Group type: EXPERIMENTAL
Intervention: naphtoxazine (SDZ‐NVI‐085)
Number of subjects: 9
Study 9579297 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 7659407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.60% NaCl solution
Number of subjects: 12
Study 7659407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% NaCl solution
Number of subjects: 12
Study 2719727 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 rads of lymphoid irradiation
Number of subjects: 20
Study 2719727 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 rads of lymphoid irradiation
Number of subjects: 20
Study 2719727 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 20
Study 30265319 — intervention group
Group type: EXPERIMENTAL
Intervention: P. spumarius nymphs
Number of subjects: 72
Study 30265319 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant infestation rate in Lecce province (infected area)
Number of subjects: 72
Study 30265319 — intervention group
Group type: EXPERIMENTAL
Intervention: Host plant selection
Number of subjects: 72
Study 28216190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive messaging iBook
Number of subjects: 106
Study 28216190 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective messaging video
Number of subjects: 106
Study 28216190 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 25450120 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal adduction stretching with manual scapular stabilization (n=30)
Number of subjects: 60
Study 25450120 — intervention group
Group type: COMPARATOR
Intervention: Horizontal adduction stretching without stabilization (n=30)
Number of subjects: 60
Study 23265334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 1376
Study 23265334 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 1376
Study 23265334 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of time spent in sinus rhythm
Number of subjects: 1376
Study 21210833 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser treatment
Number of subjects: 42
Study 21210833 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 42
Study 19329457 — intervention group
Group type: COMPARATOR
Intervention: 0% hydrogen peroxide
Number of subjects: 65
Study 19329457 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6% hydrogen peroxide
Number of subjects: 65
Study 19329457 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide
Number of subjects: 65
Study 19329457 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% hydrogen peroxide
Number of subjects: 65
Study 16827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350mJ/2Hz) with Fuji II LC (GC)
Number of subjects: 20
Study 16827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350mJ/2Hz) with Vitremer (3M)
Number of subjects: 20
Study 16827024 — intervention group
Group type: COMPARATOR
Intervention: Carbide bur (control group) with Fuji II LC (GC)
Number of subjects: 20
Study 16827024 — intervention group
Group type: COMPARATOR
Intervention: Carbide bur (control group) with Vitremer (3M)
Number of subjects: 20
Study 16827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350mJ/2Hz) with Fuji II LC (GC) on dentin
Number of subjects: 20
Study 16827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (350mJ/2Hz) with Vitremer (3M) on dentin
Number of subjects: 20
Study 16827024 — intervention group
Group type: COMPARATOR
Intervention: Carbide bur (control group) with Fuji II LC (GC) on dentin
Number of subjects: 20
Study 16827024 — intervention group
Group type: COMPARATOR
Intervention: Carbide bur (control group) with Vitremer (3M) on dentin
Number of subjects: 20
Study 16167748 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group (sips of water within 6-8 hours, followed by oral soup or milk at least 150 millilitres at a time within 8-12 hours post-operative)
Number of subjects: 192
Study 16167748 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group
Number of subjects: 192
Study 16167748 — intervention group
Group type: COMPARATOR
Intervention: Routine feeding group (restricted oral intake for 24 hours, administration of oral sips of water 24-48 hours post-operative)
Number of subjects: 192
Study 16167748 — intervention group
Group type: COMPARATOR
Intervention: Routine feeding group
Number of subjects: 192
Study 11153864 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark group (learning a route on a map that included landmarks)
Number of subjects: 67
Study 11153864 — intervention group
Group type: COMPARATOR
Intervention: No-landmark group (learning a route on a map without landmarks)
Number of subjects: 67
Study 8956916 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 129
Study 8956916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 1347222 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg/kg
Number of subjects: 75
Study 1347222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepolarizing regimen with doses ranging from approximately 1.5 to 6 times the ED95, with or without a priming dose
Number of subjects: 75
Study 2939008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of probucol and colestipol (treatment group)
Number of subjects: 28
Study 2939008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 28
Study 30340627 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM) training
Number of subjects: 90
Study 30340627 — intervention group
Group type: COMPARATOR
Intervention: Standard attentional bias task (non-treatment)
Number of subjects: 90
Study 26293156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided popliteal sciatic nerve block
Number of subjects: 60
Study 26293156 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 60
Study 24794880 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cognitive Adaptation Training (CAT)
Number of subjects: 23
Study 22568773 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory-gated auricular vagal afferent nerve stimulation (RAVANS)
Number of subjects: 15
Study 22568773 — intervention group
Group type: COMPARATOR
Intervention: Nonvagal auricular stimulation (NVAS)
Number of subjects: 15
Study 20116631 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome vaccine (n=43)
Number of subjects: 90
Study 20116631 — intervention group
Group type: COMPARATOR
Intervention: Split vaccine (n=47)
Number of subjects: 90
Study 18590393 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nerve block (NB) with 0.25% 5‐8 ml bupivacaine mixed with 20‐40 mg methylprednisolone
Number of subjects: 39
Study 18590393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 39
Study 18590393 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nerve block (NB)
Number of subjects: 39
Study 15960999 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency physicians wore white coats and formal attire
Number of subjects: 111
Study 15960999 — intervention group
Group type: COMPARATOR
Intervention: Emergency physicians wore scrubs
Number of subjects: 111
Study 12468165 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Number of subjects: 2763
Study 12468165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 10627846 — intervention group
Group type: EXPERIMENTAL
Intervention: In-flight pulsations during saccades
Number of subjects: 0
Study 10627846 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7671159 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 40 IU/day i.m. (n = 17)
Number of subjects: 120
Study 7671159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ethiodronate 400 mg p.o., 15 days every 3 months (n = 23)
Number of subjects: 120
Study 7671159 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched Spanish controls)
Number of subjects: 120
Study 2248063 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (reversible inhibitor of monoamine oxidase-A)
Number of subjects: 763
Study 2248063 — intervention group
Group type: COMPARATOR
Intervention: Tricyclics
Number of subjects: 763
Study 2248063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763
Study 7312606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic gastroscopy
Number of subjects: 103
Study 7312606 — intervention group
Group type: COMPARATOR
Intervention: Barium meal
Number of subjects: 103
Study 31917283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucidosphaerium sp. (MS)
Number of subjects: 0
Study 29718385 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 (10 mg)
Number of subjects: 518
Study 29718385 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 (25 mg)
Number of subjects: 518
Study 29718385 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 (50 mg)
Number of subjects: 518
Study 29718385 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 (100 mg)
Number of subjects: 518
Study 29718385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 28809935 — intervention group
Group type: EXPERIMENTAL
Intervention: PM+ (Problem Management Plus)
Number of subjects: 421
Study 28809935 — intervention group
Group type: COMPARATOR
Intervention: EUC (Enhanced Usual Care)
Number of subjects: 421
Study 24219753 — intervention group
Group type: EXPERIMENTAL
Intervention: Early urinary catheter clamping protocol
Number of subjects: 0
Study 24219753 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 23246078 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 234
Study 23246078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 23246078 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 234
Study 23246078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer
Number of subjects: 234
Study 21488933 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 93
Study 21488933 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking or oscillated
Number of subjects: 93
Study 17659838 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency TENS (n=81)
Number of subjects: 163
Study 17659838 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (n=82)
Number of subjects: 163
Study 17659838 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency TENS
Number of subjects: 163
Study 16720619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr Atkins' new diet revolution
Number of subjects: 100
Study 16720619 — intervention group
Group type: EXPERIMENTAL
Intervention: Slim‐Fast plan
Number of subjects: 100
Study 16720619 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers pure points programme
Number of subjects: 100
Study 16720619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary Conley's eat yourself slim diet and fitness plan
Number of subjects: 100
Study 16720619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 15241356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 0
Study 15241356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of 4 bacterial species (MIX)
Number of subjects: 0
Study 15241356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10940952 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training
Number of subjects: 196
Study 10940952 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 196
Study 9075631 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas training (60 hip flexions in sitting position with a 5 kg weight on the knee) for 3 years
Number of subjects: 67
Study 9075631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psoas training) for 3 years
Number of subjects: 67
Study 9075631 — intervention group
Group type: COMPARATOR
Intervention: Crossover from control to training after 1 year
Number of subjects: 67
Study 8471409 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vanoxerine after fasting
Number of subjects: 12
Study 8471409 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vanoxerine after low-fat meal
Number of subjects: 12
Study 3803702 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaprazole 600 mg
Number of subjects: 12
Study 3803702 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaprazole 900 mg
Number of subjects: 12
Study 3803702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29571915 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealer (AH Plus)
Number of subjects: 61
Study 29571915 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioceramic sealer (Total Fill)
Number of subjects: 61
Study 29571915 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 61
Study 27821601 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokerface poster campaign
Number of subjects: 9851
Study 27821601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9851
Study 25015535 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 112
Study 25015535 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 112
Study 22577648 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket preservation (SP) with bovine bone mineral and porcine collagen membrane
Number of subjects: 41
Study 22577648 — intervention group
Group type: COMPARATOR
Intervention: Extraction alone (EXT)
Number of subjects: 41
Study 20819587 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 311
Study 20819587 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (r-Sak or rt-PA)
Number of subjects: 311
Study 20819587 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI
Number of subjects: 311
Study 20819587 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with rescue PCI
Number of subjects: 311
Study 18308888 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking programme (WP)
Number of subjects: 152
Study 18308888 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (FA/B12/B6)
Number of subjects: 152
Study 18308888 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity placebo activity programme
Number of subjects: 152
Study 18308888 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 152
Study 15644824 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 141
Study 15644824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 12618057 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline alone (n = 10)
Number of subjects: 95
Study 12618057 — intervention group
Group type: COMPARATOR
Intervention: Levopoda/Carbidopa alone (n = 49)
Number of subjects: 95
Study 12618057 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline and Levodopa/Carbidopa combined (n = 36)
Number of subjects: 95
Study 10391253 — intervention group
Group type: COMPARATOR
Intervention: Cold perfusion temperature (20 degrees C)
Number of subjects: 291
Study 10391253 — intervention group
Group type: COMPARATOR
Intervention: Tepid perfusion temperature (32 degrees C)
Number of subjects: 291
Study 10391253 — intervention group
Group type: COMPARATOR
Intervention: Warm perfusion temperature (37 degrees C)
Number of subjects: 291
Study 10391253 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 291
Study 8894721 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezius microcurrent therapy
Number of subjects: 30
Study 8894721 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlobe microcurrent stimulation (CES)
Number of subjects: 30
Study 8894721 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study 1815069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 100 mg sulpiride
Number of subjects: 27
Study 1815069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 100 mg sulpiride
Number of subjects: 27
Study 6404341 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose prednisolone (33 patients)
Number of subjects: 67
Study 6404341 — intervention group
Group type: COMPARATOR
Intervention: Low dose prednisolone (34 patients)
Number of subjects: 67
Study 31001673 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day
Number of subjects: 296
Study 31001673 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (control)
Number of subjects: 296
Study 30505604 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.1 mg kg‐1) and tramadol (1 mg kg‐1)
Number of subjects: 88
Study 30505604 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.5 μg kg‐1 bolus followed by 0.25‐0.5 μg kg‐1 min‐1 infusion)
Number of subjects: 88
Study 26990931 — intervention group
Group type: EXPERIMENTAL
Intervention: R-COMP (rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone)
Number of subjects: 414
Study 26990931 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone)
Number of subjects: 414
Study 26990931 — intervention group
Group type: EXPERIMENTAL
Intervention: R-COMP
Number of subjects: 414
Study 26990931 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 414
Study 23834392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inhalation of beta2-agonists (salbutamol, formoterol, salmeterol)
Number of subjects: 30
Study 22230919 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectorated saliva osmolality measured during dehydration trials
Number of subjects: 12